GlassScriptPhysician profile
Jennifer D Bauer
NPI 1790875698
$7,265.74
in general payments reported to CMS, 2019-2025
26 companies · $2,568 in 2025
The $2,568 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $827 · 2023: $1,459 · 2024: $2,107 · 2025: $2,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,774 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,774.34 |
| Education | $358.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,089.47 | 2022-2025 | Adbry |
| Janssen Biotech, INC. | $1,048.85 | 2021-2025 | Tremfya |
| Abbvie INC. | $940.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $646.41 | 2022-2025 | |
| Genzyme Corporation | $561.09 | 2021-2025 | |
| Pfizer INC. | $342.49 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $333.45 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $272.29 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $255.79 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $250.45 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $247.76 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $244.72 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $225.15 | 2023-2025 | Nemluvio, Aklief |
| Incyte Corporation | $185.10 | 2022-2025 | Opzelura, Opzelura |
| Ani Pharmaceuticals, INC. | $154.55 | 2023-2025 | Purified Cortrophin Gel |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $116.23 | 2022-2025 | Sotyktu |
| Blueprint Medicines Corporation | $68.28 | 2024 | Ayvakit |
| Helsinn Therapeutics (U.S.), INC. | $66.30 | 2022-2024 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.54 | 2023-2024 | Spevigo |
| Mallinckrodt Hospital Products INC. | $41.90 | 2022 | |
| Dermavant Sciences, INC. | $34.03 | 2023 | Vtama |
| Lnhc, INC | $24.91 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $17.74 | 2024 | Ycanth |
| Organon LLC | $16.85 | 2024-2025 | Vtama |
| Fresenius Kabi USA, LLC | $15.70 | 2024 | Idacio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.